Sodium-glucose cotransporter 2 inhibitors were associated with a 33% lower risk of bleeding (HR 0.669) compared to non-use in anticoagulated patients with atrial fibrillation.
Cohort (n=102,640)
Sí
Does SGLT2i use reduce bleeding, hospitalizations, and other adverse outcomes in anticoagulated patients with atrial fibrillation?
In a large real-world cohort of anticoagulated patients with atrial fibrillation, SGLT2 inhibitor use was associated with significantly lower risks of bleeding, AF-related hospitalizations, arrhythmias, and mortality.
Estimación del efecto: HR 0.669 (95% CI 0.642-0.697)
Tasa de eventos absoluta: 7.5% vs 11.8%
valor p: p=<0.001
SGLT2i use was associated with a lower risk of AF-related complications.
Fawzy et al. (Thu,) conducted a cohort in Atrial fibrillation (n=102,640). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) vs. Non-SGLT2i use was evaluated on Bleeding (HR 0.669, 95% CI 0.642-0.697, p=<0.001). Sodium-glucose cotransporter 2 inhibitors were associated with a 33% lower risk of bleeding (HR 0.669) compared to non-use in anticoagulated patients with atrial fibrillation.